Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (401-410 of 438) with videos related to

Pageof 44
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
NPJ Precision Oncology|April 1, 2022
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapyTimothy Rajakumar, Rastislav Horos, Julia Jehn, et al.
Pageof 44

Showing results (401-410 of 438) with videos related to

Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
NPJ Precision Oncology|April 1, 2022
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapyTimothy Rajakumar, Rastislav Horos, Julia Jehn, et al.
Pageof 44